Sagimet Biosciences Inc. Series A Common Stock Income Statement
Concept
Total Revenue
YoY
Cost of Goods Sold (COGS)
Gross Profit
Operating expenses
Selling, General & Administrative
Research & Development
Operating Income
Interest Expense
Income Before Tax
Tax Provision
Net Income
YoY
Total Expenses
Net Interest Income
EBITDA
Reconciled Depreciation
EBIT
2023
2022
2021
2020
2019
2M
-
0M
2M
33M
13M
20M
-31M
0M
-28M
0M
-28M
-8.60%
33M
2M
-31M
0M
-31M
0M
-
0M
0M
31M
6M
25M
-31M
0M
-30M
0M
-30M
24.78%
31M
1M
-31M
0M
-31M
0M
-
0M
0M
24M
4M
19M
-24M
0M
-24M
0M
-24M
114.97%
24M
0M
-24M
0M
-24M
0M
-
0M
0M
11M
3M
8M
-11M
0M
-11M
0M
-11M
-20.27%
11M
0M
-11M
0M
-11M
0M
-
0M
0M
14M
6M
8M
-14M
0M
-14M
0M
-14M
-20.27%
14M
0M
-14M
0M
-14M
Concept
Total Revenue
YoY
Cost of Goods Sold (COGS)
Gross Profit
Operating expenses
Selling, General & Administrative
Research & Development
Operating Income
Interest Expense
Income Before Tax
Tax Provision
Net Income
YoY
Total Expenses
Net Interest Income
EBITDA
Reconciled Depreciation
EBIT
4Q2023
3Q2023
2Q2023
1Q2023
4Q2022
3Q2022
2Q2022
1Q2022
1Q2021
1Q2020
0M
-
0M
0M
9M
4M
6M
-9M
0M
-8M
0M
-8M
13.29%
9M
1M
-9M
0M
-9M
2M
-
0M
2M
9M
4M
5M
-7M
0M
-6M
0M
-6M
-14.92%
9M
1M
-7M
0M
-7M
0M
-
0M
0M
7M
2M
5M
-7M
0M
-7M
0M
-7M
-4.46%
7M
0M
-7M
0M
-7M
0M
-
0M
0M
7M
2M
4M
-7M
0M
-7M
0M
-7M
-24.59%
7M
0M
-7M
0M
0M
0M
-
0M
0M
7M
2M
6M
-7M
0M
-7M
0M
-7M
29.69%
7M
0M
-7M
0M
0M
0M
-
0M
0M
8M
1M
7M
-8M
0M
-7M
0M
-7M
87.47%
8M
0M
-8M
0M
-8M
0M
-
0M
0M
7M
1M
6M
-7M
0M
-7M
0M
-7M
87.47%
7M
0M
-7M
0M
0M
0M
-
0M
0M
9M
3M
6M
-9M
0M
-9M
0M
-9M
87.47%
9M
0M
-9M
0M
0M
0M
-
0M
0M
5M
1M
3M
-5M
0M
-6M
0M
-6M
87.47%
5M
0M
-5M
0M
0M
0M
-
0M
0M
4M
1M
3M
-4M
0M
-4M
0M
-4M
87.47%
4M
0M
-4M
0M
0M